Moran Wealth Management LLC Grows Stake in DexCom, Inc. $DXCM

Moran Wealth Management LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 443.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 153,333 shares of the medical device company’s stock after purchasing an additional 125,104 shares during the quarter. Moran Wealth Management LLC’s holdings in DexCom were worth $10,318,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Brighton Jones LLC raised its position in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares during the last quarter. Advisors Asset Management Inc. grew its stake in DexCom by 6.1% during the first quarter. Advisors Asset Management Inc. now owns 12,674 shares of the medical device company’s stock valued at $866,000 after acquiring an additional 726 shares in the last quarter. Integrated Wealth Concepts LLC increased its holdings in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares during the last quarter. UniSuper Management Pty Ltd lifted its stake in DexCom by 6.2% in the 1st quarter. UniSuper Management Pty Ltd now owns 40,554 shares of the medical device company’s stock worth $2,769,000 after purchasing an additional 2,377 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its holdings in shares of DexCom by 17.0% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 4,680 shares of the medical device company’s stock valued at $320,000 after purchasing an additional 681 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

DXCM stock opened at $70.10 on Thursday. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25. The stock has a market cap of $27.34 billion, a PE ratio of 38.94, a P/E/G ratio of 1.26 and a beta of 1.48. The company has a 50-day moving average price of $63.73 and a 200 day moving average price of $72.31.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter last year, the firm earned $0.45 earnings per share. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on DXCM. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of DexCom in a report on Monday, December 29th. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. The Goldman Sachs Group decreased their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a report on Wednesday, October 1st. Wells Fargo & Company set a $93.00 target price on DexCom and gave the company an “overweight” rating in a research report on Friday, October 31st. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $84.00 target price on shares of DexCom in a report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.61.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach purchased 18,200 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were purchased at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the acquisition, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the transaction, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 7,866 shares of company stock worth $448,177 in the last quarter. 0.32% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.